Passage BIO, Inc. (PASG) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 95 transactions totaling $53.6M, demonstrating a bullish sentiment with $51.4M in net insider flow. The most recent transaction on Jan 8, 2026 involved a transaction of 5,000 shares valued at $0.
No significant insider buying has been recorded for PASG in the recent period.
No significant insider selling has been recorded for PASG in the recent period.
Based on recent SEC filings, insider sentiment for PASG is bullish with an Insider Alignment Score of 98/100 and a net flow of $51.4M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Passage BIO, Inc. (PASG) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading PASG stock, having executed 95 transactions in the past 90 days. The most active insider is Capital Gp VII Llc Orbimed (Executive), who has made 16 transactions totaling $11.6M.
Get notified when executives and directors at PASG file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Borthwick Kathleen | CFO | Option Exercise | 5,000 | $N/A | $0 | C-Suite |
| Jan 8, 2026 | Borthwick Kathleen | CFO | Sale | 2,062 | $18.44 | $38.0K | C-Suite |
| Jan 8, 2026 | Borthwick Kathleen | CFO | Option Exercise | 5,000 | $N/A | $0 | C-Suite |
| Jan 8, 2026 | Chou William | Executive | Option Exercise | 10,000 | $N/A | $0 | |
| Jan 8, 2026 | Chou William | Executive | Sale | 4,076 | $18.44 | $75.2K | |
| Jan 8, 2026 | Chou William | Executive | Option Exercise | 10,000 | $N/A | $0 | |
| Sep 15, 2025 | Nichols Weston | Executive | Purchase | 11,900 | $6.99 | $83.2K | |
| Sep 12, 2025 | Nichols Weston | Executive | Purchase | 19,783 | $6.99 | $138.3K | |
| Sep 11, 2025 | Nichols Weston | Executive | Purchase | 325 | $6.96 | $2.3K | |
| Jul 24, 2025 | Management Lp Lynx1 Capital | Executive | Purchase | 66,423 | $5.71 | $379.3K | |
| Jul 23, 2025 | Management Lp Lynx1 Capital | Executive | Purchase | 49,302 | $5.74 | $283.0K | |
| Jul 22, 2025 | Management Lp Lynx1 Capital | Executive | Purchase | 13,123 | $5.44 | $71.4K | |
| Jan 15, 2025 | Chou William | Executive | Award | 20,000 | $N/A | $0 | |
| Jan 15, 2025 | Borthwick Kathleen | CFO | Award | 10,000 | $N/A | $0 | C-Suite |
| Sep 19, 2024 | Llc Orbimed Advisors | Executive | Sale | 39,300 | $0.71 | $27.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 40 | $52.5M | 97.8% |
Sale(S) | 21 | $1.1M | 2.0% |
Exercise(M) | 16 | $97.3K | 0.2% |
Award(A) | 2 | $0 | 0.0% |
Conversion(C) | 16 | $0 | 0.0% |
Insiders at Passage BIO, Inc. are accumulating shares at an accelerated pace. With 24 insiders making 95 transactions totaling $52.5M in purchases versus $1.1M in sales, the net buying activity of $51.4M signals strong executive confidence. Capital Gp VII Llc Orbimed (Executive) leads the buying activity with $11.6M in transactions across all time.